Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 1;10(11):1222-1224.
doi: 10.1001/jamacardio.2025.3109.

Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan

Kosuke Inoue  1   2   3 , Sérgio R R Decker  1   4   5 , Ivy Shi  1   6 , Lichen Liang  1 , Yang Song  1 , Sadiya S Khan  7 , Dhruv S Kazi  1   4
Affiliations

Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan

Kosuke Inoue et al. JAMA Cardiol. .
No abstract available

Plain language summary

This cohort study evaluates frequencies and predictors of discontinuation of injectable semaglutide in older adults with diabetes in the US and Japan.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Inoue reported consulting fees from Cancerscan, Cykinso, and Mizkan outside the submitted work. Dr Khan reported grants from NHLBI outside the submitted work. No other disclosures were reported.

References

    1. Marso SP, Bain SC, Consoli A, et al. ; SUSTAIN-6 Investigators . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141 - DOI - PubMed
    1. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349 - DOI - PMC - PubMed
    1. Horii T, Masudo C, Takayanagi Y, Oikawa Y, Shimada A, Mihara K. Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data. J Diabetes Investig. 2024;15(11):1578-1584. doi: 10.1111/jdi.14265 - DOI - PMC - PubMed
    1. Uzoigwe C, Liang Y, Whitmire S, Paprocki Y. Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Ther. 2021;12(5):1475-1489. doi: 10.1007/s13300-021-01053-7 - DOI - PMC - PubMed
    1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. ; SELECT Trial Investigators . Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi: 10.1056/NEJMoa2307563 - DOI - PubMed

LinkOut - more resources